Primary Screening with CETSA
Primary screening based on Cellular Thermal Shift Assay (CETSA) allows for rapid identification of high quality chemical starting points against the native, full-length protein in live cells.
The supplier does not provide quotations for this product through SelectScience. You can search for similar products in our Product Directory.
Primary screening with CETSA is a service that offers high-throughput screening of compound libraries . This method can measure and quantify the binding of compounds to their targets in live cells, in lead generation. enabling you to quickly identify the most promising hit compounds for the next stage of drug discovery. This approach can save time, money and reduce attrition rates in drug discovery.
With our primary screening with CETSA service, you can benefit from:
- Rapid assay development, without a need to engineer a cell line or to modify compounds
- High Throughput assay suitable even for challenging targets including non-enzymatic proteins or targets not amenable to purification
- Identification of high quality compound hits
Our primary screening service can be applied in the lead generation stage for rapid identification of novel chemical starting points.
Enhancing research on bifunctional degraders
CETSA® (Cellular Thermal Shift Assay) is a method used in the study of interactions between small molecules and their protein targets. It is particularly useful in targeted protein degradation (TPD), providing valuable insights into degradation profiles. TPD represents a transformative approach in drug discovery yet is still only at the foundations of exploration. Discover how CETSA can elevate advances in monitoring molecular events to elucidate molecular dynamics and cellular effects to benefit pharmaceutical solutions.
AstraZeneca Enhances Drug Discovery with Pelago Bioscience's CETSA® Assay
Pelago Bioscience offers high-throughput screening service based on CETSA® - a transformative, label-free assay for target engagement quantification in physiologically relevant context. In this case study, the CETSA® assay has been exemplified with AstraZeneca's screening of 500,000 compounds on a protein target, demonstrating superior hit rates and a six-month time-saving advantage.
Navigating drug discovery in complex environments with Pelago Bioscience
Understanding biological processes is crucial in complex environments, therefore having wider knowledge of the physiological environment improves success in drug discovery, which is often uncertain. Explore CETSA® from Pelago Bioscience, the sophisticated technology used to assess cellular protein-ligand binding. Unlike other target engagement methods, CETSA allows assessment and quantification in cellular environments under actual physiological conditions – without the need to modify the compound or protein.
